The PD-1/PD-L1 signaling pathway has become the hot spot of current immunotherapy for gastric cancer, and targeting M2-type TAMs is a practical approach to modulate the activity of anti-PD-1/PD-L1 agents. This evidence concerns the gene CD274 and gastric cancer.